Quick Links


    Print



Click for Playbook Priorities
Click for what's new
Click for Background on PrEP


Pre-exposure prophylaxis, or PrEP, is a strategy that involves the use of antiretroviral medications (ARVs) to reduce the risk of HIV infection via sexual exposure. The US Food and Drug Administration (FDA) has approved daily oral TDF/FTC as PrEP. Additional background information available here.


Priorities for the Year

AVAC's Playbook sets out top strategic goals and priorities in HIV prevention for ourselves—and for the world. Here's what we have to say about PrEP. For more, visit www.avac.org/playbook.

AVAC Playbook Image: PrEP


What's New


PrEP Watch 2.0 Launched

  • The online clearinghouse has a new look and has been expanded to include new advocacy tools, the latest trial data, and more
  • Watch this short video introductory video, What is PrEP?

PrEP Webinars

Join us April 3 to speak with medical professionals about the issues surrounding prescribing PrEP; more details here


The Latest Information on PrEP Research

  • Women & PrEP using daily oral TDF/FTC or TDF - What the science tells us (PDF)
  • HIV Prevention Research & Development in South Africa (PDF)
  • ARV-Based Prevention Research and Development Product Pipeline (PDF)(JPEG)
  • Ongoing and Planned PrEP Trials and Demonstration Projects (PDF)
  • PrEP Trials Efficacy and Adherence (PDF)(JPEG)

PrEP Update: From the American Journal of Preventative Medicine


Background on PrEP

Pre-exposure prophylaxis, or PrEP, is a strategy that involves use of antiretroviral medications (ARVs) to reduce the risk of HIV infection via sexual exposure.

All of the current effectiveness and follow-on trials are testing tenofovir-based regimens—using either TDF/FTC (an antiretroviral containing tenofovir (TDF) and emtricitabine (FTC) that is sold under the brand name Truvada) or TDF (an antiretroviral pill marketed under the brand name Viread).

Based on the data that have been collected to date the US Food and Drug Administration (FDA) announced its approval of daily oral TDF/FTC for PrEP. This is the first ARV to be approved for HIV prevention in HIV-negative adults.

You can get around the PrEP section via the links below (each list includes a few key resources from the section). Refine your search for PrEP materials on our research literacy database.

Introductory Information


More...

Ongoing Trials and Recent Results


More...

In-depth PrEP Resources


More...

Last updated: January 29, 2013


AVAC: Global Advocacy for HIV Prevention
101 West 23rd Street   ·  New York, NY  
+1 212.796.6423 (main)   ·  avac@avac.org
Copyright 2014, All rights reserved.
Design by Lomangino Studio | Powered by Orchid Suites Orchid ver. 4.7.6.